Navigation Links
Resverlogix Issues a Management Statement
Date:10/7/2008

TSX Exchange Symbol: RVX

CALGARY, Oct. 7 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that in light of the recent significant market drop of Resverlogix shares management feels it is prudent to restate that the company fundamentals remain the same if not stronger in regards to the Company's science and business developments. There is no reason for the price drop other than the current global conditions. Management will present an update as to the current business development discussions at the Annual General Meeting on October 28th, at the Telus Convention Centre in Calgary Alberta at 2:00pm

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's disease and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit http://www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.


'/>"/>
SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
2. Resverlogix is Presenting at IAS HDL Workshop
3. Resverlogix Honoured with World Economic Forum Technology Pioneer Award
4. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
5. Resverlogix Share Option Extension
6. Resverlogix Notice of Conference Call & Webcast
7. /C O R R E C T I O N from Source -- Resverlogix Corp./
8. Industry Leaders Select Resverlogixs RVX-208
9. Resverlogixs Lead Drug Featured in Key Scientific Publication
10. Jan Gray Joins Resverlogix Board of Directors
11. Resverlogix Notice of Conference Call & Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... ... July 27, 2017 , ... ... cancer research and precision medicine, today announced that its LiquidBiopsy rare cell and ... Health System. Located in Gangnam-Gu, Seoul, Severance Hospital is one of the oldest ...
(Date:7/26/2017)... ... July 26, 2017 , ... ... news outlet had initiated coverage on Aytu Bioscience and sees significant upside potential ... , According to Soulstring, Aytu Bioscience is continuing to demonstrate substantial success in ...
(Date:7/26/2017)... ... July 26, 2017 , ... ... analytics solutions, today announced that its Anzo Smart Data Lake® (Anzo SDL) ... & Information Industry Association (SIIA) CODiE Awards. , Cambridge Semantics’ Anzo SDL ...
(Date:7/26/2017)... ... July 25, 2017 , ... The leading Regenerative Veterinary Medicine ... cell therapy has been used on more than 13,000 animals. VetStem was ... fatal injuries to tendons and ligaments. , In 2003 VetStem signed a worldwide ...
Breaking Biology Technology:
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/30/2017)... HONG KONG , March 30, 2017 ... developed a system for three-dimensional (3D) fingerprint identification by adopting ground ... technology into a new realm of speed and accuracy for use ... applications at an affordable cost. ... ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
Breaking Biology News(10 mins):